Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 123

1.

Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.

Soloway MS, Soloway CT, Williams S, Ayyathurai R, Kava B, Manoharan M.

BJU Int. 2008 Jan;101(2):165-9. Epub 2007 Sep 10.

PMID:
17850361
[PubMed - indexed for MEDLINE]
2.

Prostate biopsy: who, how and when. An update.

Djavan B, Milani S, Remzi M.

Can J Urol. 2005 Feb;12 Suppl 1:44-8; discussion 99-100. Review.

PMID:
15780165
[PubMed - indexed for MEDLINE]
4.

Expectant management of stage A-1 (T1a) prostate cancer utilizing serum PSA levels: a preliminary report.

Loughlin KR, Renshaw AA, Kumar S.

J Surg Oncol. 1999 Jan;70(1):49-53. Review.

PMID:
9989421
[PubMed - indexed for MEDLINE]
5.

[Management of prostate cancer with indolent biological potential: from watchful waiting to active surveillance].

Leibovici D, Lindner A, Stay K, Zisman A.

Harefuah. 2006 Oct;145(10):763-7, 781, 780. Review. Hebrew.

PMID:
17111715
[PubMed - indexed for MEDLINE]
6.

Clinically unsuspected and undetected (clinical stage t0) prostate cancer diagnosed on random needle biopsy.

Corica FA, Bostwick DG.

Urology. 1999 Mar;53(3):557-60. Review.

PMID:
10096384
[PubMed - indexed for MEDLINE]
7.

An evidence review of active surveillance in men with localized prostate cancer.

Ip S, Dahabreh IJ, Chung M, Yu WW, Balk EM, Iovin RC, Mathew P, Luongo T, Dvorak T, Lau J.

Evid Rep Technol Assess (Full Rep). 2011 Dec;(204):1-341. Review.

PMID:
23126653
[PubMed - indexed for MEDLINE]
Free Article
8.

Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer.

Klotz L.

Eur Urol. 2005 Jan;47(1):16-21. Review.

PMID:
15582244
[PubMed - indexed for MEDLINE]
9.

[PSA and follow-up after treatment of prostate cancer].

Benchikh El Fegoun A, Villers A, Moreau JL, Richaud P, Rebillard X, Beuzeboc P.

Prog Urol. 2008 Mar;18(3):137-44. doi: 10.1016/j.purol.2007.12.010. Epub 2008 Apr 18. Review. French.

PMID:
18472065
[PubMed - indexed for MEDLINE]
10.

Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.

Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL.

Ann Intern Med. 2008 Mar 18;148(6):435-48. Epub 2008 Feb 4. Review. Erratum in: Ann Intern Med. 2008 Jun 3;148(11):888.

PMID:
18252677
[PubMed - indexed for MEDLINE]
11.

Insignificant prostate cancer and active surveillance: from definition to clinical implications.

Bastian PJ, Carter BH, Bjartell A, Seitz M, Stanislaus P, Montorsi F, Stief CG, Schröder F.

Eur Urol. 2009 Jun;55(6):1321-30. doi: 10.1016/j.eururo.2009.02.028. Epub 2009 Mar 6. Review.

PMID:
19286302
[PubMed - indexed for MEDLINE]
12.

[Prostate cancer: Diagnosis and staging].

Fournier G, Valeri A, Mangin P, Cussenot O.

Ann Urol (Paris). 2004 Oct;38(5):207-24. Review. French.

PMID:
15570705
[PubMed - indexed for MEDLINE]
13.

[Stage T1a prostatic cancer: long-term retrospective study of 27 patients].

Descazeaud A, Zerbib M, Conquy S, Amsellem-Ouazana D, Saighi D, Debré B.

Prog Urol. 2001 Sep;11(4):662-6. Review. French.

PMID:
11761687
[PubMed - indexed for MEDLINE]
14.

Treatment of localized prostate cancer: when is active surveillance appropriate?

Albertsen PC.

Nat Rev Clin Oncol. 2010 Jul;7(7):394-400. doi: 10.1038/nrclinonc.2010.63. Epub 2010 May 4. Review.

PMID:
20440282
[PubMed - indexed for MEDLINE]
15.

Active surveillance versus radical treatment for favorable-risk localized prostate cancer.

Klotz L.

Curr Treat Options Oncol. 2006 Sep;7(5):355-62. Review.

PMID:
16904052
[PubMed - indexed for MEDLINE]
16.

Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer.

Klotz L.

Nat Clin Pract Urol. 2005 Mar;2(3):136-42; quiz 1 p following 149. Review.

PMID:
16474710
[PubMed - indexed for MEDLINE]
17.

Is routine digital rectal examination required for the followup of prostate cancer?

Warren KS, McFarlane JP.

J Urol. 2007 Jul;178(1):115-9. Epub 2007 May 11. Review.

PMID:
17499293
[PubMed - indexed for MEDLINE]
18.

Tumour serum markers: clinical and economical aspects.

Kardamakis D.

Anticancer Res. 1996 Jul-Aug;16(4B):2285-8. Review.

PMID:
8694557
[PubMed - indexed for MEDLINE]
19.

Active surveillance: the Canadian experience.

Klotz L.

Curr Opin Urol. 2012 May;22(3):222-30. doi: 10.1097/MOU.0b013e328352598c. Review.

PMID:
22453335
[PubMed - indexed for MEDLINE]
20.

Active surveillance in men with localized prostate cancer: a systematic review.

Dahabreh IJ, Chung M, Balk EM, Yu WW, Mathew P, Lau J, Ip S.

Ann Intern Med. 2012 Apr 17;156(8):582-90. doi: 10.7326/0003-4819-156-8-201204170-00397. Epub 2012 Feb 20. Review.

PMID:
22351515
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk